Context and Expectancy in Psychedelic Research

Why this topic matters

Psychedelic experiences can be intense and easy to recognize. That creates special problems for research: people who get the drug often know it, people who get a placebo often know that too, and what everyone expects can shape what happens. This page explains those problems in plain terms. It is the library's main page on context and expectancy; other pages link here rather than repeat it.

Set, setting and expectancy

The US National Institute on Drug Abuse (NIDA) says effects of psychedelic and dissociative drugs are hard to predict and depend on factors including a person's biology, age, personality, mood, expectations, mindset (commonly called "set") and environment ("setting"). [1]

A 2016 paper compares two bodies of thought: placebo response theory and set and setting theory. Both treat expectancy, preparation and beliefs as crucial for understanding how non-biological factors shape the response to a drug. They differ in that set and setting concerns psychoactive drugs only, while placebo theory covers all therapeutic interventions. [2] The paper notes that set and setting theory has traditionally been prescriptive, advising therapists and users. This library does not give that kind of advice.

Blinding and "functional unblinding"

In a good drug trial, people do not know whether they received the drug or a placebo; this is called blinding. With psychedelics, the effects can be so obvious that blinding breaks down. FDA's 2026 guidance calls this functional unblinding and says it can lead to expectation bias in patients who experience perceptual disturbances, or in those who observe them. [3] A person who receives a placebo and notices nothing may expect no benefit, and a person who notices strong effects may expect benefit. [3]

A 2021 review of psychedelic randomized trials found that most had not reported pre-trial expectancy or whether blinding had worked, and argued that effect sizes are likely over-estimated because of de-blinding and high response expectancy. [4]

A 2022 methods review adds that the significant media hype about psychedelics influences participants' expectations, and that unmasking and expectation can interact so that psychedelic therapy is highly susceptible to large placebo and nocebo effects. [5] (A nocebo effect is a harmful or unwanted response caused by negative expectations.)

What regulators suggest

FDA's guidance says a traditional inert placebo can be problematic for judging efficacy, although it helps with safety findings, and that alternatives such as lower doses of a psychedelic or other psychoactive drugs may be considered. [3] It suggests blinded central raters, questionnaires asking people what they think they received, and questionnaires about expectations before and after treatment. [3] It also notes that enrolling people with prior psychedelic experience raises the possibility of expectation bias, since they are more likely to recognize the effects. [3]

FDA further states that the contribution of the psychotherapy component to any efficacy has not been characterized, and that the therapist watching a session can often deduce which treatment was given. [3]

What this means for the evidence

• Label: mixed. Many psychedelic trials report large effects, but reviewers say expectancy and unblinding may inflate them. [4]
• Label: insufficient evidence for how much of any benefit comes from the drug itself, the psychological support, or expectation. FDA says this has not been characterized. [3]
• A registered trial or protocol is not a positive result, and a positive trial without good blinding checks should be read with caution.

Context is not a recipe

Research context includes screening, preparation and monitoring by trained teams. Describing these as research features is different from giving them as steps for anyone to follow outside research. This site does not provide such steps. For what clinical settings do, see What "Preparation" Means in Clinical Settings and Clinical Research vs Recreational Use.

Related pages

• How to Read a Psychedelic Clinical Trial
• Placebo and Expectancy in Microdosing
• Proposed Mechanisms vs Proven Clinical Outcomes

Education only

This page explains research methods. It does not recommend any substance or any way to use one.